Approaches to mitigating the sexual dysfunction associated with SSRI treatment include lowering dosage, switching antidepressant medications, or adding concomitant medications such as a phosphodiesterase inhibitor type 5 (PDE5; e.g., sildenafil), a norepinephrine-dopamine reuptake inhibitor (e.g., bupropion), or a 5-HT1A receptor partial agonist (e.g., buspirone) (Rizvi and Kennedy 2013). The gene discussed is HTR1A; the disease is sexual dysfunction.